{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-261689","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.437943+00:00","generated_at":"2026-05-17T00:55:20.471337+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pyxis Oncology Q3 net loss $22.0M; cash $77.7M, runway into H2 2026","bullets":["Net loss $22.0M ($0.35/share) for Q3 2025, vs $21.2M loss in Q3 2024.","Cash and equivalents $77.7M; expected to fund operations into H2 2026.","R&D expenses $17.8M; increase in MICVO costs offset by pause of PYX-106 program.","Preliminary Phase 1 data for micvotabart pelidotin (MICVO) in HNSCC expected in Q4 2025.","Translational data presented at ESMO and AACR-NCI-EORTC on MICVO's three mechanisms of action."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-261689","json":"https://secwatch.observer/filing/0001193125-25-261689.json","markdown":"https://secwatch.observer/filing/0001193125-25-261689.md","text":"https://secwatch.observer/filing/0001193125-25-261689.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000119312525261689/0001193125-25-261689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000119312525261689/pyxs-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:55:20.471337+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}